abstract |
The present invention relates to the treatment of cancer. NUPR1 is a nuclear intrinsically disordered protein (IDP) of 82 amino acids long that play an important role in pancreatic ductal adenocarcinoma (PDAC) as well as other cancers since its genetic inactivation by genetic or pharmacological approaches induces tumors growth arrest and/or regression. The inventors recently developed an efficient multidisciplinary strategy by combining biophysical, biochemical, bioinformatic and biological approaches for a molecular screening to select potential drug candidates against NUPR1. A family of TFP-derived compounds was produced and the most active one, named ZZW-115, showed more than 10 times efficient antitumor activity on a large panel of primary PDAC-derived cells and several non-pancreatic cancer cells. More, they showed that treatment with ZZW-115 sensitizes cancer cells to genotoxic-induced DNA damage. Thus, the present invention relates to a combination of an inhibitor of NUPR1 and a genotoxic treatment for use in the treatment of a cancer in a subject in need thereof. Particularly, the invention is defined by its claims. |